Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Brainsway Ltd. (OTC: BRSYF).

Full DD Report for BRSYF

You must become a subscriber to view this report.

Recent News from (OTC: BRSYF)

Neuronetics Is Undervalued, There Seems To Be A 40% Upside Potential
Neuronetics (STIM) recently released a solid quarterly report that included 30.94% revenue growth and a massive amount of cash. Almost 90% of its total amount of assets is represented by cash. The market did not seem to assess the figures reported and pushed the stock price down in November. A...
Source: SeekingAlpha
Date: November, 25 2018 22:12
More on Brainsway Q2 results
Brainsway ( OTCPK:BRSYF ) reports Q2  revenue growth of 54.2% Y/Y to $3.7M. More news on: Brainsway Ltd., Read more ...
Source: SeekingAlpha
Date: August, 27 2018 10:37
GE's Bet On Neuronetics: Sell It At 8.32x Forward Sales
Neuronetics, Inc. ( STIM ) is now trading at 8.32x forward sales after delivering a decent quarterly release with 28.5% revenue growth. The valuation seems too high if we compare with other peers, thus it may be time to liquidate the position. In this piece, there is further due diligence on...
Source: SeekingAlpha
Date: August, 21 2018 14:35
3 Things In Biotech, August 18: Finally, A New First-Line Treatment For Liver Cancer
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Eisai and Merck's liver cancer partnership pays off Company: Eisai ( OTCPK:ESALY ) and M...
Source: SeekingAlpha
Date: August, 20 2018 11:32
FDA clears BrainsWay's Deep TMS for obsessive compulsive disorder
The FDA grants 510(k) clearance for BrainsWay Ltd.'s ( OTCPK:BRSYF ) deep transcranial magnetic stimulation ( Deep TMS ) system for the treatment of adults with obsessive compulsive disorder (OCD), the first such clearance for a non-invasive medical device for the condition. More news on...
Source: SeekingAlpha
Date: August, 20 2018 10:26
Brainsway reports Q1 results
Brainsway ( OTCPK:BRSYF ): Q1 Revenue of $3.6M (+71.4% Y/Y). More news on: Brainsway Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 29 2018 07:03
Brainsway reports FY results
Brainsway ( OTCPK:BRSYF ): FY Revenue of $11.1M (-3.5% Y/Y) Press Release More news on: Brainsway Ltd., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: March, 19 2018 16:35


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BRSYF.

About Brainsway Ltd. (OTC: BRSYF)

Logo for Brainsway Ltd. (OTC: BRSYF)

BrainsWay is dedicated to developing and providing advanced technology solutions for the treatment of a variety of brain disorders. The company was established in , and became a public company traded on the Tel Aviv Stock Exchange in January . BrainsWay s flagship technology is Deep TMS, or Deep Transcranial Magnetic Stimulation, which launches a new era in brain disorder treatment.




Current Share Structure

  • Market Cap: $53,230,365 - 05/11/2018
  • Issue and Outstanding: 11,828,970 - 12/15/2011


Daily Technical Chart for (OTC: BRSYF)

Daily Technical Chart for (OTC: BRSYF)

Stay tuned for daily updates and more on (OTC: BRSYF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BRSYF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BRSYF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BRSYF and does not buy, sell, or trade any shares of BRSYF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: